Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.

Inclusion Criteria: * Provision of signed, informed consent * Age \>18 years * HIV infection documented by HIV antibody test and Western Blot prior to study entry * No previous ART OR no ART for 6 months prior to randomisation * CD4+ count of \<500 cells/mm or viral load \>10,000 copies/ml within 60 days prior to randomisation * No genotypic resistance to Raltegravir, Tenofovir/emtricitabine, Darunavir, Ritonavir * Body mass index less than 30kg/m2 Exclusion Criteria: * Primary HIV infection within the last 6 months * Active infection or opportunistic illness within the previous 30 days * Use of any medication contra-indicated with ritonavir-boosted darunavir or raltegravir * Use of lipid-lowering therapy * Diabetes mellitus (fasting glucose \>7.0mml/l or a prior diagnosis of diabetes) * Use of oral prednisolone \> 7.5mg daily or equivalent * pregnancy or Breast feeding * proven hypersensitivity to one or more components of the study meal